SCHEDULE 13G: Five Narrow Lane LP Discloses 9.99% Passive Stake in GT Biopharma, Inc.

Five Narrow Lane LP has reported a passive beneficial ownership of 9.99% in GT Biopharma, Inc., holding 253,388 shares of common stock.

Summary

• Five Narrow Lane LP has filed a Schedule 13G with the SEC, disclosing its beneficial ownership in GT Biopharma, Inc.
• The reporting entity, Five Narrow Lane LP, beneficially owns 253,388 shares of GT Biopharma, Inc.'s common stock.
• This ownership stake represents 9.99% of the total outstanding shares of GT Biopharma, Inc.
• The percentage ownership is calculated based on 2,536,397 shares of common stock outstanding as of February 28, 2025, as reported in a Form 424B3 filed on March 14, 2025.
• Five Narrow Lane LP holds sole voting power and sole dispositive power over all 253,388 shares.
• The aggregate amount of shares beneficially controlled by Five Narrow Lane LP is subject to a contractually stipulated 9.99% ownership restriction.
• The filing certifies that the securities were acquired and are held for passive investment purposes and not with the intent to change or influence the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It indicates a significant, passive investment by Five Narrow Lane LP.

Future Outlook

The document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding GT Biopharma, Inc.'s future performance or strategic outlook.

Management Comments

• Arie Rabinowitz, Managing Member of the General Partner of Five Narrow Lane LP, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of GT Biopharma, Inc., nor were they acquired or held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This Schedule 13G filing is a routine disclosure of a significant passive ownership stake by an institutional investor in a biopharmaceutical company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant, albeit passive, institutional stake by Five Narrow Lane LP could be perceived as a signal of confidence in GT Biopharma, Inc., potentially influencing investor sentiment.

Key Dates

Keywords

GT Biopharma, Five Narrow Lane LP, Schedule 13G, beneficial ownership, common stock, passive investment, equity stake, biopharma